These nanovaccines not only could prolong tumor-occurring time, inhibit tumor growth by 76.6%, and suppress tumor metastasis in prophylactic, therapeutic, and metastatic melanoma models, but also could enhance IFN-γ secretion and CD8+ T cell response (Figure 4B-D) 84. The gene discussed is IFNG; the disease is neoplasm.